Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785841
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785841
Biomarker Clinical Phase Outsourcing Services
PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Biomarker Clinical Phase Outsourcing Services Market to Reach US$28.7 Billion by 2030
The global market for Biomarker Clinical Phase Outsourcing Services estimated at US$9.2 Billion in the year 2024, is expected to reach US$28.7 Billion by 2030, growing at a CAGR of 20.8% over the analysis period 2024-2030. Predictive Biomarkers, one of the segments analyzed in the report, is expected to record a 20.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Prognostic Biomarkers segment is estimated at 21.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 19.7% CAGR
The Biomarker Clinical Phase Outsourcing Services market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 19.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.9% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.
Global Biomarker Clinical Phase Outsourcing Services Market - Key Trends & Drivers Summarized
Why Is the Demand for Biomarker Clinical Phase Outsourcing Services Rising?
The rapid expansion of precision medicine and targeted therapies has significantly increased the need for biomarker-based clinical trials, leading pharmaceutical and biotechnology companies to outsource key phases of biomarker development. Biomarker clinical phase outsourcing services encompass a wide range of functions, including biomarker validation, patient stratification, bioanalytical testing, and regulatory compliance support. As drug development processes become more complex and data-driven, outsourcing these critical phases to specialized contract research organizations (CROs) is becoming an essential strategy to streamline operations and accelerate time-to-market. Additionally, the growing prevalence of chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions has fueled the need for biomarker-driven diagnostics and therapeutic solutions. Biomarkers play a crucial role in predicting disease progression, assessing treatment responses, and minimizing adverse effects, making them indispensable for modern clinical trials. As pharmaceutical companies strive to develop highly personalized treatment regimens, the demand for outsourced biomarker services is surging, allowing them to leverage the expertise, infrastructure, and regulatory proficiency of specialized CROs.
How Are Technological Advancements Transforming Biomarker Outsourcing Services?
Technological innovations are revolutionizing the biomarker outsourcing landscape, enabling faster, more accurate, and cost-effective clinical phase studies. Advances in genomics, proteomics, and metabolomics have led to the discovery of novel biomarkers, improving early disease detection and therapeutic monitoring. AI and machine learning are further enhancing biomarker data analysis, allowing researchers to identify meaningful patterns and correlations from vast datasets, optimizing patient selection, and improving trial success rates. Moreover, the integration of next-generation sequencing (NGS) and digital pathology in biomarker analysis is providing more precise insights into disease mechanisms. These technologies are improving the efficiency of companion diagnostics and enhancing the development of targeted therapies. Additionally, the use of liquid biopsy techniques is gaining traction in biomarker-based clinical trials, allowing for real-time monitoring of disease progression through minimally invasive procedures. As these technological advancements continue to shape biomarker development, outsourcing services are becoming increasingly sophisticated, offering more comprehensive and tailored solutions for pharmaceutical and biotech companies.
What Market Trends Are Driving the Growth of Biomarker Clinical Phase Outsourcing Services?
One of the most prominent trends shaping the biomarker outsourcing market is the increasing focus on personalized medicine. As healthcare shifts from a one-size-fits-all approach to more individualized treatment strategies, the need for biomarker-driven drug development has intensified. Pharmaceutical firms are leveraging biomarker outsourcing services to conduct specialized clinical trials that identify patient subgroups most likely to benefit from specific therapies, improving treatment outcomes and regulatory approval chances. Another key market trend is the rise of decentralized and virtual clinical trials. With advancements in digital health technologies and remote patient monitoring, biomarker research is expanding beyond traditional clinical settings. CROs are increasingly offering remote biomarker collection, AI-driven analytics, and cloud-based data management solutions, enhancing the efficiency and accessibility of outsourced clinical trial phases. Furthermore, regulatory agencies such as the FDA and EMA are promoting biomarker-driven drug approvals, further encouraging pharmaceutical companies to invest in outsourced biomarker validation and testing services.
What Are the Key Growth Drivers for the Biomarker Clinical Phase Outsourcing Services Market?
The growth in the Biomarker Clinical Phase Outsourcing Services market is driven by several factors, including the increasing complexity of clinical trials, rising demand for personalized medicine, and advancements in biomarker research technologies. The high costs and resource-intensive nature of biomarker development have made outsourcing an attractive option for pharmaceutical companies seeking to optimize their drug pipelines and reduce operational burdens. The globalization of clinical trials is also contributing to market expansion, as outsourcing enables pharmaceutical firms to conduct multi-regional biomarker studies while ensuring compliance with regulatory requirements. Additionally, the growing adoption of AI and big data analytics in biomarker research is streamlining data interpretation and improving clinical trial efficiencies. With continuous innovations in precision medicine and biomarker discovery, the market for outsourced biomarker clinical phase services is expected to witness exponential growth, positioning CROs as indispensable partners in the future of drug development and personalized healthcare.
SCOPE OF STUDY:
The report analyzes the Biomarker Clinical Phase Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Biomarker Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints); Therapeutic Area (Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 48 Featured) -
- Celerion
- Charles River Laboratories
- Clario
- Eurofins Scientific SE
- GenScript Biotech Corporation
- ICON Plc
- IQVIA
- Laboratory Corporation of America Holdings
- NorthEast BioAnalytical Laboratories LLC
- Parexel International Corporation
- Proteome Sciences
- Syneos Health
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Product Code: MCP29591
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Biomarker Clinical Phase Outsourcing Services - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Surge in Biomarker-Driven Drug Development Pipelines Throws the Spotlight on Clinical Phase Outsourcing Services
- Rising Complexity of Multimodal Biomarkers Drives Demand for Specialized Clinical Validation Expertise
- Increased Use of Companion Diagnostics in Oncology Spurs Outsourcing of Biomarker-Enriched Trials
- Regulatory Push for Stratified Trial Designs Strengthens Business Case for Biomarker-Driven Patient Segmentation
- Expansion of Immunotherapy and Precision Medicine Trials Accelerates Need for Outsourced Biomarker Operations
- Growth in Liquid Biopsy and Non-Invasive Monitoring Platforms Fuels Demand for Flexible Clinical Trial Models
- OEM Focus on Accelerating Time-to-IND and Time-to-Approval Drives Adoption of Biomarker CRO Partnerships
- Emergence of Multi-Omic and Digital Biomarkers Expands Technical Capabilities Required From Service Providers
- Increased Integration of Central Lab and Site Network Services Enhances Operational Continuity in Biomarker Trials
- Use of AI for Adaptive Trial Design and Endpoint Prediction Supports Outsourced Biomarker Optimization
- Rise in Real-World Evidence and Post-Market Studies Reinforces Role of Biomarkers in Longitudinal Monitoring
- Globalization of Multicenter Trials Promotes Outsourcing of Biomarker Logistics and Compliance Management
- OEM Partnerships With Bioinformatics Firms Enhance Clinical Interpretation of High-Dimensional Biomarker Data
- Regulatory Harmonization Across FDA, EMA, and PMDA Supports Outsourced Global Biomarker Development
- Increasing Use of Circulating Tumor DNA and RNA Biomarkers Drives Sample Handling and Data Processing Outsourcing
- OEM Demand for Centralized Data Platforms and Biomarker Traceability Strengthens Outsourced Model Preference
- Growth in Rare Disease Trials and Niche Patient Populations Fuels Biomarker-Centric Outsourcing Models
- OEM Investment in Risk-Based Monitoring and Decentralized Trials Expands Biomarker Data Capture Models
- Availability of Qualified Biomarker Banks and Retrospective Analysis Services Supports Late-Phase Trial Value
- Cost-Containment and Operational Efficiency Objectives Drive Long-Term Outsourcing in Biomarker-Enriched Clinical Trials
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Predictive Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 2: World 6-Year Perspective for Predictive Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Prognostic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 4: World 6-Year Perspective for Prognostic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Safety Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World 6-Year Perspective for Safety Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Surrogate Endpoints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 8: World 6-Year Perspective for Surrogate Endpoints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 9: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 10: World 6-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World 6-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 14: World 6-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 15: World Recent Past, Current & Future Analysis for Autoimmune Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 16: World 6-Year Perspective for Autoimmune Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 20: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 21: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 22: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 25: World Biomarker Clinical Phase Outsourcing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 28: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 29: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 30: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 31: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- CANADA
- TABLE 34: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 35: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 36: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 37: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- JAPAN
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 40: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 41: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 42: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 43: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- CHINA
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 46: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 47: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 48: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 49: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- EUROPE
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 52: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 53: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 54: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 55: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- TABLE 58: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 59: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- FRANCE
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 60: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 61: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 64: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 65: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- GERMANY
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 66: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 67: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 70: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 71: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- ITALY
- TABLE 72: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 73: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 76: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 77: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- UNITED KINGDOM
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 78: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 79: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 82: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 83: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 85: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 89: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- ASIA-PACIFIC
- Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 91: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 95: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
- REST OF WORLD
- TABLE 96: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 97: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
- TABLE 100: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 101: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.